Interferon-α2a reduces MRI disease activity in relapsing-remitting multiple sclerosis

Neurology

Volumn 52, Issue 5, 1999, Pages 1049-1056

  Myhr, K M ^e   Riise, T ^f   Lilleås, F E Green ^f   Beiske, T G ^b   Celius, E G ^f   Edland, A ^c   Jensen, D ^f   Larsen, J P ^d   Nilsen, R ^a   Nortvedt, M W ^f   Smievoll, A I ^f   Vedeler, C ^f   Nyland, H I ^f  

^a Roche Norway   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c Buskerud Central Hospital   (Norway)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GADODIAMIDE; RECOMBINANT ALPHA2A INTERFERON; ALPHA2A INTERFERON;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TIME;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERFERON ALFA-2A; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033596756     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.5.1049     Document Type: Article

References (40)

1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Ann Rev Immunol 1992;10: 153-187.
2. The IFNB Multiple Sclerosis Study Group. Interteron beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
3. Paty DW, Li DK, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
5. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
6. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276.
7. Fazekas F, Deisenhammer F, Strasser Fuchs S, Nahler G, Mamoli B, the Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomized placebo controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-593.
8. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenic and clinical implications. Brain 1990;113:1477-1489.
9. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
10. Tyring SK. Introduction to clinical use of interferons. In: Baron S, Coppenhaver DH, Dianzani F, et al., eds. Interferon, principles and medical applications. Galveston, TX: The University of Texas Medical Branch, 1992:399-408.
11. Izumo S, Goto I, Itoyama Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996;46:1016-1021.
12. Martin R, Hohlfeld R. Current immunotherapy of multiple sclerosis. Clin Immunother 1996;5(suppl 1):12-21.
13. Knobler RL, Panitch HS, Braheny SL, et al. Systemic alpha-interferon therapy of multiple sclerosis. Neurology 1984;34: 1273-1279.
14. Camenga DL, Johnson KP, Alter M, et al. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 1986;43:1239-1246.
15. AUSTIMS Research Group. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry 1989; 52:566-574.
16. Kastrukoff LF, Oger JJ, Hashimoto SA, et al. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 1990;40: 479-486.
17. Kinnunen E, Timonen T, Pirttila T, et al. Effects of recombinant alpha-2b-interferon therapy in patients with progressive MS. Acta Neurol Scand 1993;87:457-460.
18. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-413.
19. Quesada JR. Toxicity and side effects of interferons. In: Baron S, Coppenhaver DH, Dianzani F, et al., eds. Interferon: principles and medical applications. Galveston, TX: The University of Texas Medical Branch, 1992:327-432.
20. Krown SE. Clinical trials of interferons in human malignancy. In: Pfeffer LM, ed. Mechanisms of interferon actions, vol II. Boca Raton, FL: CRC Press, 1987:144-178
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
22. Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-1372.
23. Ware JE. SF-36 Health Survey manual and interpretation guide. Boston: Nimrod Press, 1993.
24. Goldberg D, Williams P. A user's guide to the General Health Questionnaire. Berkshire, UK: NFER-Nelson, 1991.
25. Nauta JJ, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 1994;122:6-14.
26. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
27. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: WHO Offset Publications, 1979.
28. Hennes U, Jucker W, Fischer EA, et al. The detection of antibodies to recombinant interferon alfa-2a in human serum. J Biol Stand 1987;15:231-244.
29. Durelli L, Bongioanni MR, Ferrero B, et al. Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology 1996;47:123-129.
30. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991;114:1057-1067.
31. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
32. Calabresi PA, Stone LA, Bash CN, Frank JA, McFarland HF. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997;48:1446-1448.
33. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995;45:255-260.
34. Porres JC, Carreno V, Ruiz M, Marron JA, Bartolome J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol 1989;8:351-357.
35. Steis RG, Smith JW 2d, Urba WJ, et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988;318:1409-1413.
36. Bonetti P, Diodati G, Drago C, et al. Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol 1994;20: 416-420.
37. Oger J, Vorobeychick G, Al-Fahim A, Aziz T, Edan G, Paty DW. Neutralizing antibodies in betaseron-treated MS patients and in vitro immune function before treatment. Neurology 1997;48(suppl 2):A80.
38. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
39. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998;50:1266-1272.
40. Utsumi J, Shimizu H. Human interferon-β, protein structure and function. In: Baron S, Coppenhaver DH, Dianzani F, et al., eds. Interferon, principles and medical applications. Galveston, TX: The University of Texas Medical Branch, 1992: 107-116.